结直肠癌肝转移切除术后辅助肝动脉灌注化疗与生存改善相关且不受KRAS状态影响
KRAS野生型中HAI组5年生存78%对57%(HR 0.51,P<0.001),KRAS突变型中59%对40%(HR 0.56,P<0.001);多因素分析HAI仍与总生存改善相关(HR 0.53,P<0.002)。
要点
- CRLM切除术后辅助HAI与总生存改善独立相关,不受KRAS状态影响
- KRAS突变型患者术后预后更差,辅助HAI可能减轻这一劣势
- HAI组肿瘤特征更差但仍见生存获益,需前瞻性研究验证
核心结论
- 结直肠癌肝转移切除术后辅助HAI化疗与结局改善独立相关,且不受KRAS突变状态影响。
- 辅助HAI可能减轻可切除KRAS突变型CRLM患者较差的预后。
研究设计与样本
- 单中心回顾性分析,来自MSKCC前瞻性维护的机构数据库,纳入674例切除的CRLM患者(418例KRAS野生型、256例突变型)。
主要发现
- KRAS野生型中,HAI组5年生存78%,无HAI组57%(HR 0.51,P<0.001)。
- KRAS突变型中,HAI组5年生存59%,无HAI组40%(HR 0.56,P<0.001)。
- 多因素分析中HAI仍与总生存改善相关(HR 0.53,P<0.002),独立于KRAS状态及其他临床病理因素。
- HAI组同步发病、病灶数目、临床风险评分、二期肝切除等肿瘤特征显著更差,但无HAI组切除肝外转移者更多。
临床怎么用
- 对CRLM根治性切除术后患者,尤其KRAS突变型等高危人群,可考虑辅助HAI以改善生存。
- 决策时需结合肝外转移、肝切除范围等肿瘤特征个体化评估HAI的适用性。
局限性
- 为单中心回顾性分析,存在选择偏倚,HAI组肿瘤特征更差提示非随机分组。
- 研究跨越1993至2012年,方案与围术期管理可能随年代变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the impact of adjuvant hepatic artery infusion (HAI) in relation to KRAS mutational status in patients with resected colorectal cancer liver metastases (CRLM). BACKGROUND: Patients with KRAS-mutated CRLM have worse outcomes after resection. Adjuvant HAI chemotherapy improves overall survival after liver resection. METHODS: Patients with resected CRLM treated at MSKCC with and without adjuvant HAI who had available KRAS status (wild-type, WT; mutated, MUT) were reviewed from a prospectively maintained institutional database. Correlations between KRAS status, adjuvant HAI, clinical factors, and outcomes were analyzed. Cox proportional hazard model was used to adjust for confounders. RESULTS: Between 1993 and 2012, 674 patients (418 KRAS-WT, 256 MUT) with a median follow up of 6.5 years after resection were evaluated. Fifty-four percent received adjuvant HAI. Tumor characteristics (synchronous disease, number of lesions, clinical-risk score, 2-stage hepatectomy) were significantly worse in the HAI group; however, there were more patients with resected extrahepatic metastases in the no-HAI group. In KRAS-WT tumors, 5-year survival was 78% for patients treated with HAI versus 57% for patients without HAI [hazard ratio (HR) 0.51, P < 0.001]. In KRAS-MUT tumors, 5-year survival was 59% for patients treated with HAI versus 40% for patients without HAI (HR 0.56, P < 0.001). On multivariate analysis, HAI remained associated with improved OS (HR 0.53, P < 0.002) independent of KRAS status and other clinicopathologic factors. CONCLUSION: Adjuvant HAI after resection of CRLM is independently associated with improved outcomes regardless of KRAS mutational status. Adjuvant HAI may mitigate the worse outcomes seen in patients with resectable KRAS-MUT CRLM.
引用
- Gholami S, Kemeny NE, Boucher TM, et al. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. Ann Surg. 2020. PMID: 32675549. doi:10.1097/SLA.0000000000003248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。